PROGYNY INC (PGNY)
US74340E1038 - Common Stock
Taking everything into account, PGNY scores 7 out of 10 in our fundamental rating. PGNY was compared to 113 industry peers in the Health Care Providers & Services industry. PGNY gets an excellent profitability rating and is at the same time showing great financial health properties. PGNY is not overvalued while it is showing excellent growth. This is an interesting combination. With these ratings, PGNY could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year PGNY was profitable.
In the past year PGNY had a positive cash flow from operations.
PGNY had positive earnings in 4 of the past 5 years.
Of the past 5 years PGNY 4 years had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 8.68%, PGNY belongs to the top of the industry, outperforming 93.81% of the companies in the same industry.
PGNY's Return On Equity of 13.17% is amongst the best of the industry. PGNY outperforms 83.19% of its industry peers.
PGNY has a better Return On Invested Capital (12.72%) than 92.04% of its industry peers.
PGNY had an Average Return On Invested Capital over the past 3 years of 8.61%. This is in line with the industry average of 8.10%.
The 3 year average ROIC (8.61%) for PGNY is below the current ROIC(12.72%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.68% | ||
| ROE | 13.17% | ||
| ROIC | 12.73% |
ROA(3y)10.72%
ROA(5y)8.95%
ROE(3y)15.14%
ROE(5y)13.15%
ROIC(3y)8.61%
ROIC(5y)7.94%
1.3 Margins
The Profit Margin of PGNY (5.03%) is better than 84.07% of its industry peers.
PGNY's Profit Margin has declined in the last couple of years.
PGNY's Operating Margin of 5.75% is fine compared to the rest of the industry. PGNY outperforms 66.37% of its industry peers.
In the last couple of years the Operating Margin of PGNY has grown nicely.
PGNY has a Gross Margin (21.68%) which is in line with its industry peers.
PGNY's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.75% | ||
| PM (TTM) | 5.03% | ||
| GM | 21.68% |
OM growth 3Y28.9%
OM growth 5YN/A
PM growth 3Y-24.95%
PM growth 5YN/A
GM growth 3Y2.58%
GM growth 5Y3.57%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so PGNY is still creating some value.
The number of shares outstanding for PGNY has been increased compared to 1 year ago.
The number of shares outstanding for PGNY has been increased compared to 5 years ago.
PGNY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
PGNY has an Altman-Z score of 6.12. This indicates that PGNY is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of PGNY (6.12) is better than 91.15% of its industry peers.
PGNY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 6.12 |
ROIC/WACC1.41
WACC9.05%
2.3 Liquidity
A Current Ratio of 2.62 indicates that PGNY has no problem at all paying its short term obligations.
PGNY has a better Current ratio (2.62) than 84.07% of its industry peers.
PGNY has a Quick Ratio of 2.62. This indicates that PGNY is financially healthy and has no problem in meeting its short term obligations.
PGNY has a Quick ratio of 2.62. This is amongst the best in the industry. PGNY outperforms 85.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.62 | ||
| Quick Ratio | 2.62 |
3. Growth
3.1 Past
PGNY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 67.31%, which is quite impressive.
PGNY shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 97.89% yearly.
The Revenue has grown by 10.24% in the past year. This is quite good.
The Revenue has been growing by 59.52% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)67.31%
EPS 3Y97.89%
EPS 5YN/A
EPS Q2Q%150%
Revenue 1Y (TTM)10.24%
Revenue growth 3Y46.69%
Revenue growth 5Y59.52%
Sales Q2Q%2.04%
3.2 Future
Based on estimates for the next years, PGNY will show a very strong growth in Earnings Per Share. The EPS will grow by 40.77% on average per year.
PGNY is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.90% yearly.
EPS Next Y16.81%
EPS Next 2Y11.74%
EPS Next 3Y20.8%
EPS Next 5Y40.77%
Revenue Next Year7.27%
Revenue Next 2Y4.48%
Revenue Next 3Y8.5%
Revenue Next 5Y16.9%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 17.21 indicates a rather expensive valuation of PGNY.
80.53% of the companies in the same industry are more expensive than PGNY, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of PGNY to the average of the S&P500 Index (28.96), we can say PGNY is valued slightly cheaper.
PGNY is valuated rather expensively with a Price/Forward Earnings ratio of 19.34.
PGNY's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. PGNY is cheaper than 68.14% of the companies in the same industry.
PGNY is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 23.82, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.21 | ||
| Fwd PE | 19.34 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PGNY is valued a bit cheaper than the industry average as 70.80% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, PGNY is valued cheaply inside the industry as 94.69% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.95 | ||
| EV/EBITDA | 11.84 |
4.3 Compensation for Growth
PGNY's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PGNY has a very decent profitability rating, which may justify a higher PE ratio.
PGNY's earnings are expected to grow with 20.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.02
PEG (5Y)N/A
EPS Next 2Y11.74%
EPS Next 3Y20.8%
5. Dividend
5.1 Amount
No dividends for PGNY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PROGYNY INC
NASDAQ:PGNY (11/21/2024, 8:00:01 PM)
After market: 14.8001 -0.17 (-1.13%)14.97
+0.99 (+7.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.27B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.21 | ||
| Fwd PE | 19.34 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)1.02
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.68% | ||
| ROE | 13.17% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 5.75% | ||
| PM (TTM) | 5.03% | ||
| GM | 21.68% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.62 | ||
| Quick Ratio | 2.62 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)67.31%
EPS 3Y97.89%
EPS 5Y
EPS Q2Q%
EPS Next Y16.81%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)10.24%
Revenue growth 3Y46.69%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y